Research progress in 2023 ASCO-GU prostate cancer
10.3969/j.issn.1009-8291.2023.06.015
- VernacularTitle:2023 ASCO-GU 前列腺癌研究进展快递
- Author:
Zheng CHAO
1
;
Yanan WANG
1
;
Yue GE
1
;
Qiang ZHOU
1
;
Zezhong XIONG
1
;
Sheng MA
1
;
Junbiao ZHANG
1
;
Le LI
1
;
Zhihua WANG
1
Author Information
1. Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430300, China
- Publication Type:Journal Article
- Keywords:
prostate cancer;
international conferences;
interpretation;
treatment progress
- From:
Journal of Modern Urology
2023;28(6):536-540
- CountryChina
- Language:Chinese
-
Abstract:
The 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium unveiled numerous research advances which provide meaningful insights into the selection of treatment regimens of prostate cancer. Precision multi-treatment based on patients’ characteristics has become the predominant approach, including the use of a three-drug combination therapy for metastatic hormone-sensitive prostate cancer, and poly adenosine diphosphate ribose polymerase inhibitor therapy for metastatic castration-resistant prostate cancer. Nuclear medicine therapy and radiotherapy are also receiving significant attention. Integrated nuclear medicine diagnosis and therapy show immense potential for non-metastatic castration-resistant prostate cancer. Additionally, for localized prostate cancer, stereotactic body radiotherapy is a preferred alternative to surgery. This article sheds light on several key studies presented at the conference, focuses on prostate cancer treatment at different stages, and intends to enhance the therapeutic outcome for prostate cancer patients.
